The CHMP’s recommendation will be reviewed by the European Commission (EC), which is expected to make its final decision soon. Pfizer and BioNTech have already initiated manufacturing of the ...

Pfizer is cutting costs, growing its core business, and trading at a deep discount despite looming patent losses and COVID ...

Data indicate that the LP.8.1-adapted COVID-19 vaccine confers improved immune response against currently dominant and emerging sublineages - including the XFG and NB.1.8.1 variants1 - compared to 202 ...

Global pharmaceutical giants make billions of dollars in Australia but pay a fraction of that in tax. They say the price they ...

U.S. President Donald Trump says he intends to shorten the 50-day deadline he gave Russian President Vladimir Putin to reach ...

The Trump administration is asking the Supreme Court to allow it to cut hundreds of millions of dollars’ worth of research ...

Merck has launched a sweeping cost-cutting effort designed to save $3 billion annually by the end of 2027, the company said ...

BenchSci, a world leader in AI solutions for preclinical research and drug discovery, today announced that Mikael Dolsten, M.D., Ph.D., has joined its board of directors.

Shares of GSK fell to below $30 around the time of the demerger, but have since recovered to about $36. The 20% gain over 34 ...

As the country continues to deal with the fallout of the infamous Jeffery Epstein files, The Root is taking a closer look at ...

Pharma’s next big leap won’t come from the lab. It’ll come from outside the lab, where the rules of narrative, attention, and ...

GSK has moved to shore up its R&D pipeline with a strategic-level deal with China's Jiangsu Hengrui Pharma that spans a dozen drug candidates and could be worth up to $12.5 billion.